A gloved pharmaceutical laboratory worker arranges green and white capsules in a filling tray

CruxBuzz Staff

Eli Lilly GLP-1 Pill Foundayo Approved in Canada for Weight Management

Canada, Drugs, Health, Public Health

Many adults who want to lose weight dread sticking themselves with a needle every week. For years, leading weight-loss medications required weekly shots and the discomfort of routine injections. That routine creates persistent anxiety for patients who dislike needles. A simple tablet taken by mouth offers welcome relief.

With the authorization of a new GLP-1 pill, Canada now provides an oral alternative to weekly injections. Health Canada authorized Eli Lilly’s once-daily oral pill Foundayo, the brand name for the active ingredient orforglipron, on 13 November 2026. The regulatory decision gives Canadian patients a new oral therapy for weight management.

Health Canada approved Foundayo for adults with obesity. It is also approved for adults who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea. In addition, the pill is authorized to help treat Type 2 diabetes. The daily capsule gives patients a needle-free path to manage weight and blood sugar.

For patients who prefer a pill over a weekly injection, an oral option removes a major hurdle. Patients no longer need to travel with chilled injector pens. Instead, taking a pill becomes an ordinary morning habit, swallowed with water alongside other daily prescriptions. This simple change allows more people to seek medical help comfortably.

What Foundayo Is and How Doses Are Adjusted

Foundayo is a pill taken once a day. Patients can take it at any time, with or without food. The recommended starting dose is 1 mg once daily. After at least 30 days the dose increases to 3 mg. It can then be raised to 6 mg, 12 mg, 24 mg or 36 mg. The maximum dose is 36 mg once daily. The most common side effects of GLP-1 medications, both injectable and oral, include gastrointestinal issues such as nausea or vomiting.

How the Daily Pill Compares With Weekly Injections

Foundayo enters a market shaped by weekly injections. Eli Lilly’s injectable drugs Mounjaro and Zepbound contain tirzepatide and are given weekly. Meanwhile, Novo Nordisk’s Ozempic and Wegovy contain semaglutide. Daily oral capsules provide a very different routine for patients seeking the same metabolic benefits.

Dr. Ehud Ur is an endocrinologist in Vancouver who is not associated with either company. He said of orforglipron: “It seems to be just as good as if not better” for weight loss than semaglutide and tirzepatide. He said he is waiting for clinical trial results on whether orforglipron has a cardiovascular benefit like those drugs do.

Clinicians emphasize that personal preference matters just as much as clinical trial data. Dr. Hertzel Gerstein, professor of medicine at McMaster University and Hamilton Health Sciences, said: “You treat a patient, not a disease. Some people would prefer the injection once a week and then forget about it. Some people will prefer the pill.”

Cost, Availability and What Comes Next

Patients will not have to wait long to access the treatment. Eli Lilly spokesperson Ethan Pigott said the company expects the pills to be available in pharmacies in January.

Foundayo will soon face oral competition. Novo Nordisk’s Rybelsus is another GLP-1 pill on the market in Canada. However, it is only approved for Type 2 diabetes management and not for weight loss. Novo Nordisk’s Wegovy pill is awaiting Health Canada approval. Both Foundayo and the Wegovy pill are approved and available in the United States.

The two oral options rely on different technology. The semaglutide-based pill must be taken on an empty stomach. Food triggers stomach acid and digestive enzymes that can break the drug down before it is absorbed. Wegovy’s pill uses an enhancer called SNAC to protect it. Jennifer Lake is a pharmacist and assistant professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto. She said of SNAC: “You can think about it as a cover on the drug. When you take it by mouth, that cover dissolves, but the drug never gets broken up.” She said of Foundayo: “It doesn’t matter if you take it with food or not. This really is a big flexibility for how people normally take medications once a day when it fits in their schedule.”

The two oral therapies are not equivalent on convenience. Foundayo is a small non-peptide molecule that can be taken with or without food. The semaglutide pill needs an empty stomach, because food-triggered acid and enzymes destroy it before absorption. That daily difference in meal timing, rather than the drug class, is what most patients will act on.

Do you have to take Foundayo on an empty stomach?

No. Foundayo is taken once a day with or without food. That is the main convenience difference from the semaglutide pill, which must be taken on an empty stomach.

Health Canada’s authorization of Foundayo provides a needle-free option for adults managing obesity, overweight health risks, and Type 2 diabetes. Watch for the pills to arrive in Canadian pharmacies in January. In the months ahead, regulators will decide on the Wegovy pill, while researchers deliver trial results on cardiovascular protection.

Leave a Comment